Avalo Therapeutics
AVTX
13.58
-0.01
-0.07%
Avalo Therapeutics
US · AVTX
#3484 by market cap
13.58
-0.01
-0.07%
Live - 5344 symbols - heartbeat 307s ago
· 2026-10-08 08:02
Pre-market
14.14
+4.12%
After-hours
13.58
0.00%
- Market cap
- 728.30M
- P/E (TTM)i
- -3.08
- P/Bi
- 1.62
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.7 percentage points.
Institutional ownership
- Held by institutions
- 136.44% -0.71pp
- Institutions
- 152 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund64.86%
Mutual Fund45.73%
VC/PE Fund18.62%
Public Company5.76%
Individual/Insider1.54%
Sovereign Wealth Fund0.84%
Private Company0.42%
Insurance Company0.17%
Top holders as of 2026-07-31
FMR
10.70% · 5.74M sh
BlackRock
8.14% · 4.37M sh
Deep Track Capital, LP
6.73% · 3.61M sh
Caligan Partners, LP
5.90% · 3.16M sh
TCG Crossover Management, LLC
5.63% · 3.02M sh
Affinity Asset Advisors, LLC
5.41% · 2.90M sh
State Street Global Advisors
5.39% · 2.89M sh
Vanguard Capital Management, LLC
4.83% · 2.59M sh
Farallon Capital Management, L.L.C.
4.66% · 2.50M sh
Point72 Asset Management, L.P.
4.45% · 2.39M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Patrick Crutcher | Former Chief Strategy Officer | 1.02% |
| Garry Neil | Chairperson & CEO | 0.35% |
| Christopher Sullivan | CFO & Head of Investor relations | 0.07% |
| Paul Varki | Chief Legal Officer | 0.02% |
| Mittie Doyle | Chief Medical Officer | 0.02% |
| Aaron Kantoff | Independent Director | 0.01% |
| Samantha Truex | Independent Director | 0.01% |
| Gilla Kaplan | Independent Director | 0.01% |
| June Almenoff | Independent Director | 0.01% |
| Jonathan Goldman | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Kevin Lind | Director | Other Derivative Acquisition | +1,352 | $15.33 |
| 2026-09-29 | Rita Jain | Director | Other Derivative Acquisition | +1,322 | $15.33 |
| 2026-09-29 | Ron Philip | Independent Director | Other Derivative Acquisition | +1,109 | $15.33 |
| 2026-09-15 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -12,394 | $9.88–16.33 |
| 2026-09-09 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -10,185 | $8.04–17.62 |
| 2026-08-27 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -679 | $8.04–20.00 |
| 2026-08-17 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -71,852 | $9.88–20.05 |
| 2026-08-16 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,000 | $12.65–20.00 |
| 2026-08-16 | Christopher Sullivan | CFO & Head of Investor relations | Open Market Disposition | -873 | $19.94 |
| 2026-08-10 | Jennifer Riley | Chief Strategy Officer | Open Market Disposition | -2,655 | $19.59 |
| 2026-08-09 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -679 | $8.04–20.00 |
| 2026-07-26 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,000 | $12.65–20.00 |
| 2026-06-29 | Kevin Lind | Director | Other Derivative Acquisition | +1,105 | $18.48 |
| 2026-06-29 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -4,654 | $8.04–20.00 |
| 2026-06-29 | Rita Jain | Director | Other Derivative Acquisition | +1,080 | $18.48 |
| 2026-06-29 | Ron Philip | Independent Director | Other Derivative Acquisition | +69 | $18.48 |
| 2026-06-22 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,450 | $8.04–18.00 |
| 2026-06-22 | Ron Philip | Independent Director | Other Derivative Acquisition | +40,200 | $17.83 |
| 2026-06-09 | Mittie Doyle | Chief Medical Officer | Sale to Issuer | -1,084 | $13.10 |
| 2026-06-09 | Paul Varki | Chief Legal Officer | Sale to Issuer | -1,081 | $13.10 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:02:58 · For reference only, not investment advice and not tailored to your situation.